Profile data is unavailable for this security.
About the company
Zhejiang Starry Pharmaceutical Co Ltd is a China-based company mainly engaged in the research and development, production and sales of pharmaceutical specialty raw materials. The Company's business includes the production and sales of intermediates, APIs and preparations of iodine contrast agent series products such as iohexol, iopamidol, iodixanol, iomeprol, ioversol and iopromide. The Company's main products are non-ionic iodine contrast agent series drugs, levofloxacin series products, levofloxacin APIs and intermediates.
- Revenue in CNY (TTM)2.39bn
- Net income in CNY-29.25m
- Incorporated1997
- Employees1.75k
- LocationZhejiang Starry Pharmaceutical Co LtdXianjuTAIZHOU 317306ChinaCHN
- Phone+86 57 687718605
- Fax+86 57 687718686
- Websitehttps://www.starrypharm.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhejiang Starry Pharmaceutical Co Ltd | 2.39bn | -29.25m | 4.61bn | 1.75k | -- | 1.77 | -- | 1.93 | -0.1149 | -0.1149 | 5.84 | 5.93 | 0.4078 | 1.78 | 5.62 | 1,363,012.00 | -0.4978 | 2.04 | -0.8498 | 3.75 | 18.98 | 27.73 | -1.22 | 5.05 | 0.4035 | 0.6728 | 0.5007 | 78.73 | 7.02 | 12.42 | -211.00 | -- | 29.24 | -3.43 |
| Yabao Pharmaceutical Group Co Ltd | 2.27bn | 222.85m | 4.66bn | 3.61k | 21.19 | 1.69 | -- | 2.05 | 0.3177 | 0.3177 | 3.26 | 3.99 | 0.6462 | 3.42 | 6.66 | 629,532.00 | 5.51 | 4.01 | 6.54 | 5.38 | 50.46 | 56.75 | 8.53 | 5.86 | 2.49 | -- | 0.0418 | 54.27 | -7.69 | -2.46 | 21.60 | 77.16 | -26.08 | 71.88 |
| Obio Technology Shanghai Corp Ltd | 244.64m | -294.16m | 4.69bn | 692.00 | -- | 3.08 | -- | 19.18 | -0.4578 | -0.4578 | 0.3819 | 2.35 | 0.1095 | 4.22 | 2.37 | 353,519.30 | -13.15 | -3.10 | -15.68 | -3.47 | -37.29 | 19.60 | -120.16 | -23.22 | 1.06 | -94.99 | 0.2068 | -- | 21.16 | 31.58 | -151.54 | -- | 36.17 | -- |
| Jinyao Pharmaceutical Co Ltd | 2.87bn | 16.30m | 4.71bn | 2.88k | 282.25 | 1.56 | -- | 1.64 | 0.0153 | 0.0153 | 2.63 | 2.77 | 0.49 | 2.45 | 6.38 | 996,743.00 | 1.39 | 1.87 | 2.18 | 3.31 | 41.43 | 45.67 | 2.84 | 3.30 | 1.19 | 11.91 | 0.1563 | 65.00 | -15.00 | -0.6786 | 14.01 | -3.78 | -23.40 | 19.63 |
| Ningbo Menovo Pharmaceutical Co Ltd | 1.54bn | 99.48m | 4.72bn | 2.47k | 47.53 | 2.04 | -- | 3.06 | 0.4502 | 0.4502 | 7.00 | 10.49 | 0.329 | 1.23 | 5.91 | 623,207.90 | 2.34 | 3.98 | 3.68 | 6.21 | 32.03 | 34.08 | 7.11 | 12.00 | 0.7165 | 5.71 | 0.3482 | 11.27 | 12.85 | 3.07 | 476.64 | -15.04 | -11.37 | -8.68 |
| Sinotherapeutics Inc | 480.48m | 98.59m | 4.74bn | 312.00 | 48.05 | 3.62 | -- | 9.86 | 0.2175 | 0.2175 | 1.06 | 2.89 | 0.333 | 2.74 | 4.51 | 1,539,987.00 | 6.83 | 10.22 | 7.32 | 11.26 | 43.78 | 65.76 | 20.52 | 31.88 | 11.08 | -- | 0.00002 | 13.77 | 70.61 | 29.80 | 109.09 | 94.07 | 32.01 | -- |
| Pulike Biological Engineering Inc | 1.10bn | 143.67m | 4.86bn | 1.55k | 33.40 | 1.88 | -- | 4.40 | 0.4204 | 0.4204 | 3.22 | 7.45 | 0.3571 | 2.68 | 3.03 | 711,690.80 | 4.65 | 6.79 | 5.41 | 8.00 | 57.65 | 62.55 | 13.02 | 16.34 | 2.51 | 15.83 | 0.0005 | 61.54 | -16.77 | 9.47 | -46.82 | -3.21 | 7.28 | 14.87 |
| Shanghai Xiao Fang Pharmaceutical Co Ltd | 504.59m | 213.50m | 4.87bn | 404.00 | 22.67 | 4.61 | -- | 9.64 | 1.33 | 1.33 | 3.16 | 6.57 | 0.3795 | 3.71 | 4.85 | 1,248,981.00 | 16.06 | -- | 19.02 | -- | 65.40 | -- | 42.31 | -- | 3.47 | -- | 0.0017 | -- | 0.5748 | -- | 0.8074 | -- | -- | -- |
Data as of Feb 11 2026. Currency figures normalised to Zhejiang Starry Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
9.33%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Aegon-Industrial Fund Management Co., Ltd.as of 30 Jun 2025 | 22.95m | 6.70% |
| Galaxy Asset Management Co., Ltd.as of 30 Jun 2025 | 4.18m | 1.22% |
| CIB Fund Management Co., Ltd.as of 30 Jun 2025 | 1.90m | 0.56% |
| Xingyin Fund Management Co., Ltd.as of 30 Jun 2025 | 722.70k | 0.21% |
| HuaAn Fund Management Co., Ltd.as of 30 Jun 2025 | 696.10k | 0.20% |
| Huatai Securities (Shanghai) Asset Management Co., Ltd.as of 30 Jun 2025 | 390.20k | 0.11% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 308.14k | 0.09% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2025 | 302.90k | 0.09% |
| Everbright PGIM Fund Management Co. Ltd.as of 30 Jun 2025 | 268.30k | 0.08% |
| BOSC Asset Management Co. Ltd.as of 30 Jun 2025 | 221.90k | 0.07% |
More ▼
Data from 30 Jun 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
